Medical Condition News

RSS

Weight training may help the elderly retain muscle

Have you ever noticed that people have thinner arms and legs as they get older? As we age it becomes harder to keep our muscles healthy. They get smaller, which decreases strength and increases the likelihood of falls and fractures. New research is showing how this happens — and what to do about it.

11 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009

Mayo study raises hope for treating multiple sclerosis

A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS). These findings give researchers new hope for developing more effective therapies for patients with MS and for predicting MS patients' outcomes. This study will be presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Dusseldorf, Germany, on Sept. 11, 2009.

11 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.

11 Sep 2009

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company’s novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE symptom severity and impact of treatment.

11 Sep 2009

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

MN Community Measurement today announced that Regions Hospital has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a new effort to improve the quality -- and equality -- of cardiac care delivered in hospitals. The Aligning Forces for Quality: Equity Quality Improvement Collaborative (Equity QI Collaborative) will identify and test ways for hospitals to improve the quality and efficiency of their cardiac care, while also identifying and reducing any racial and ethnic disparities.

11 Sep 2009

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

11 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Edward Hospital announced today that it has established the Edward Neurosciences Institute in affiliation with the Northwestern Medical Faculty Foundation to bring the highest level of stroke care in the world to the west and southwest suburbs of Chicago.

11 Sep 2009

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

11 Sep 2009

ERC funds DiaDrug project to study the link between insulin resistance and albuminuria

The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007. In total, 2503 proposals were submitted to the second Starting Grant call.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Medical institutes sponsor education newsletter series on angioedema

Angioedema is characterized by episodes of intense localized edema involving the skin, visceral organs, and airway, causing discomfort and even death as a result of airway obstruction. There are a number of therapies available for the prevention and treatment of angioedema, and new therapies are being studied to further minimize the effect of acute attacks on this patient population.

11 Sep 2009

Culinary Software adds Allergen Alerts functionality to its ChefTec software

Culinary Software Services, Inc., the leading provider of back-of-the-house technology for the foodservice industry, announces the addition of Allergen Alerts to its ChefTec software. Under the Food Allergen Labeling & Consumer Protection Act, the FDA requires food labels to clearly state if food products contain any ingredients from the eight major allergenic foods.

11 Sep 2009

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.

11 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Study investigating the effect of FTO obesity gene in relation to food habits

The risk of becoming obese is 2.5 times higher for those who have double copies of the best known risk gene for overweight and obesity. However, this is only true if the fat consumption is high. A low fat diet neutralizes the harmful effects of the gene.

11 Sep 2009

Medical Condition News

Weight training may help the elderly retain muscle

Accupac to manufacture Access Pharmaceuticals' MuGard

Mayo study raises hope for treating multiple sclerosis

Genspera to commence G-202 Phase I trial following FDA approval

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Cymbalta maintains reduction in pain for patients with chronic low back pain

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

ERC funds DiaDrug project to study the link between insulin resistance and albuminuria

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Medical institutes sponsor education newsletter series on angioedema

Culinary Software adds Allergen Alerts functionality to its ChefTec software

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

Study investigating the effect of FTO obesity gene in relation to food habits

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News